Scleroderma (Systemic Sclerosis) stem cell therapy — your questions answered (2026)

About stem cell therapy for Scleroderma (Systemic Sclerosis)

Systemic sclerosis (scleroderma) is an autoimmune disease involving fibrosis and vascular and immune dysfunction that may affect skin and internal organs. Two very different approaches must not be conflated. Autologous haematopoietic stem-cell transplantation (HSCT) is an intensive specialist treatment considered in selected people with severe, early diffuse cutaneous systemic sclerosis after careful cardiopulmonary risk assessment. Placental or other mesenchymal stromal cell (MSC) products remain investigational and have not established the same clinical role. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Scleroderma (Systemic Sclerosis)

Randomised evidence and specialist recommendations support considering autologous HSCT for carefully selected severe early diffuse disease, while recognising substantial treatment-related risk. That evidence cannot be transferred to placental MSC infusion: the products, conditioning, mechanism, risks and endpoints are fundamentally different. MSC studies remain early and heterogeneous. No combined response rate is published here. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Costs for specialist autologous HSCT and investigational MSC infusion are not comparable. HSCT involves mobilisation, conditioning chemotherapy, hospital care and prolonged monitoring; an MSC infusion is a different experimental product and procedure. Private quotations may exclude pre-treatment organ assessment, standard systemic-sclerosis care, travel and management of complications. Patients should obtain an itemised written quote and written confirmation of sponsor, insurer and patient responsibilities without treating price as evidence of benefit.

Can stem cells treat scleroderma?

Cell therapy for Scleroderma (Systemic Sclerosis) may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

HSCT vs MSC?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

Who qualifies?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Scleroderma (Systemic Sclerosis) programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Scleroderma (Systemic Sclerosis) (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Scleroderma (Systemic Sclerosis) overview · Scleroderma (Systemic Sclerosis) cost →